Without Your DEA Registration, There Is No Distribution Business.
Dhairya Jani is a former DEA Diversion Enforcement Counsel representing drug distributors, wholesale distributors, and specialty distributors in DEA administrative enforcement proceedings and civil penalty matters.
Distributor enforcement is not just about one shipment or one customer. When the DEA targets a distributor, it examines the entire system: how suspicious orders are identified, how customer due diligence is conducted, and whether the documented record matches actual practice. Jani Law PLLC represents distributors from first investigative contact through administrative hearing and final agency order.
The Regulatory Framework Distributors Operate Under
Wholesale distributors of controlled substances carry some of the most demanding regulatory obligations in the Controlled Substances Act (CSA) framework.
Beyond standard registrant requirements, distributors are held to specific obligations around suspicious order identification and reporting, customer due diligence, Automation of Reports and Consolidated Orders System (ARCOS) transaction reporting, and effective diversion controls.
The adequacy of those controls, as written, as executed, and as documented, is the central contested issue in nearly every distributor enforcement action. Distributor registration is governed by 21 U.S.C. § 823(b) and (f).
Civil penalty exposure under 21 U.S.C. § 842(c) is substantial and runs on a separate timeline from the administrative proceeding. Positions taken in the DEA administrative hearing can be used against you in the civil penalty matter. Both tracks must be managed from day one.
What the DEA Examines in a Distributor Enforcement Action
Suspicious Order Monitoring – 21 C.F.R. § 1301.74(b)
Suspicious order monitoring is the most heavily litigated area of distributor enforcement. Under 21 C.F.R. § 1301.74(b), distributors must design, operate, and document a system that identifies suspicious orders: orders of unusual size, deviating substantially from a normal pattern, or of unusual frequency.
The DEA evaluates suspicious order monitoring programs on four dimensions:
- Written protocols
- Actual execution
- Escalation procedures
- Documentation quality
Written policies without documented real-world execution provide little protection in an enforcement proceeding. A program that exists on paper but cannot be demonstrated in practice is treated as if it does not exist.
Customer Due Diligence
DEA enforcement increasingly focuses on what you knew or should have known about the downstream dispensing practices of the customers you supplied.
Continued supply to a customer exhibiting diversion red flags, including unusual volume, cash-dominant payment, or high controlled substance ratios, without documented due diligence creates direct enforcement exposure.
ARCOS Reporting — 21 C.F.R. § 1304.33
Distributors must report all Schedule I and II controlled substance transactions to the DEA through ARCOS. Reporting accuracy and completeness are subject to a DEA audit. Discrepancies between ARCOS reports and internal transaction records can become the core of an enforcement case.
Schedule II Recordkeeping — 21 C.F.R. §§ 1304.03–1304.06, 1304.11, 1304.31-1304.33
Every acquisition, transfer, and distribution of a Schedule II substance must be documented precisely: substance name, quantity, date, counterparty identity, and DEA registration number. DEA Form 222 or its electronic equivalent is required for every acquisition.
Records must be retained for two years and available for DEA inspection on demand. Even minor discrepancies between ordering, receiving, and inventory records can become enforcement findings.
Physical Security — 21 C.F.R. § 1301.72
Schedule I and II controlled substances must be stored in a vault or safe storage meeting the DEA’s construction and access standards. Investigators examine physical controls in practice, not just on paper: access logs, key and combination procedures, alarm systems, and personnel termination protocols.
The gap between written security policy and actual execution is a recurring enforcement exposure point.
How Jani Law PLLC Represents Drug Distributors
- Order to Show Cause (OSC) defense and Immediate Suspension Order (ISO) response through full administrative law judge hearing, Recommended Decision, and Administrator’s Final Order
- Investigation and inspection response, including scope management, document control, privilege analysis, and strategic management of the investigative record from the first DEA contact
- Administrative subpoena response, including scope and legal authority analysis to ensure the response is legally sound
- Suspicious order monitoring program assessment, including review of written protocols, execution documentation, escalation procedures, and documentation quality, and development of corrective procedures calibrated to the DEA’s enforcement standards
- Customer due diligence program review, including account-level risk profiling and documented escalation procedures for high-risk accounts
- Corrective Action Plan development designed to support negotiated resolution where the facts permit
- Memorandum of Agreement (MOA) negotiation, including term-by-term review, operational impact analysis, and compliance program design that meets MOA obligations without creating additional exposure
- Civil penalty matters: advising on civil penalty exposure under 21 U.S.C. § 842(c) and ensuring the administrative defense accounts for civil consequences from day one
Protect Your Business and Your Reputation as a Drug Distributor: Contact Jani Law PLLC
If you are a drug distributor facing DEA enforcement, Jani Law PLLC is on your side. As a former DEA Diversion Enforcement Counsel, Dhairya Jani brings firsthand experience of how these cases are built and where they can be challenged to defend your business and professional reputation. To request a free, confidential consultation, contact our law firm today.